Phase II study of intravenous bevacizumab (bev) and paclitaxel (pac), and intraperitoneal (ip) cisplatin (c), followed by bevacizumab (bev) maintenance, for advanced ovarian cancer: A report on progression-free survival (PFS) and toxicity

✍ Scribed by L. Perry; G. Lanneau; J. Curiel; C. Mathews; K. Moxley; L. Landrum; K. Moore; J. Walker; R. Mannel; D. McMeekin

• Book ID: 113963607
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 67 KB
• Volume: 125
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2011.12.052